Browse through our approved corporate photos. These images may be used for editorial purposes as long as the connection to Quotient is clearly recognizable. Commercial use is prohibited.
|Hand, close-up of microarray||2.1 MB||JPG|
|MosaiQ by Quotient instrument and lab technician||2.5 MB||JPG|
|MosaiQ by Quotient instrument and microarray cartridge loading dock||2.3 MB||JPG|
|Lab technicians blood sample, lab||2.5 MB||JPG|
|MosaiQ COVID-19 Antibody Microarray||6.0 MB||MP4|
|MosaiQ COVID-19 Antibody Microarray Infographic||0.2 MB|
Approved company descriptions
Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. Quotient has two key product portfolios, Alba by Quotient, quality blood bank reagents used in laboratories around the world, and MosaiQ™ by Quotient, the world’s first fully automated, consolidated testing platform. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. MosaiQ by Quotient has been recognized with a Red Dot Product Design Award.
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multimodal, multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. A serological test was developed in April 2020 in response to the global COVID-19 pandemic. The MosaiQ COVID-19 Antibody Microarray is CE marked and is the subject of an Emergency Use Authorization issued by the U.S. Food and Drug Administration. The COVID-19 antibody test is available for distribution in the U.S., the EU, the UK and Switzerland. In April 2021, the full MosaiQ by Quotient system has been recognized with a Red Dot Product Design Award. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
Meet our management team
We have over 30 years’ experience manufacturing and supplying conventional reagent products used for blood grouping within the $3.4 billion global transfusion diagnostics market. We are developing MosaiQ by Quotient, our proprietary technology platform, to better address the comprehensive needs of this large and established market. We believe MosaiQ has the potential to be a transformative technology, significantly reducing the cost of blood grouping in the donor and patient testing environments, while improving patient outcomes.
Manuel O. Méndez joined Quotient (NASDAQ:QTNT) as the company’s Chief Executive Officer in April 2021.
He brings over 30 years of experience in the diagnostics and life science markets. Mr. Méndez joins Quotient from Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services where he served as the Senior Vice President and Chief Commercial Officer. He played a key role in accelerating growth and supporting the COVID-19 efforts. Before joining Quest, he was living in Germany and served as SVP and Head of Global Commercial Operations and a member of QIAGEN N.V. Executive Committee, a worldwide provider of Sample to Insight solutions for molecular testing. Manuel has held a variety of senior leadership roles with Abbott Laboratories, Thermo Fisher Scientific, OraSure Technologies, and bioMerieux – living in the United States, Europe, Asia, and Latin America.
An American citizen, Mr. Méndez received an MBA from Northwestern University's Kellogg School of Management and a bachelor's degree in biomedical engineering from Boston University.
Peter Buhler joined Quotient (NASDAQ:QTNT) as the company’s Chief Financial Officer in February 2020. Mr Buhler has more than 20 years of experience in the strategic and financial leadership of life science and technology businesses in both the public and private sectors, more recently with Zaluvida AG, where he served as Group Chief Financial Officer.
In addition, Mr Buhler served as Group Chief Financial Officer of Greer Plc, a global leader in allergy immunotherapy headquartered in London.
While there, Mr Buhler led a complex merger project to combine a French and a US Group through the creation of a UK holding. Previously, he served as Head of Finance, Commercial Europe at Merck Serono SA and Finance Director EMEA at Logitech SA.
He is a Swiss Certified Accountant and an Executive MBA from the Swiss Business School in Zurich.
Jeremy Stackawitz joined Quotient (NASDAQ:QTNT) in 2009, overseeing the company through a period of sustained rapid growth. He led Quotient’s entry into the US market, where the company now serves over 1,000 customers and has successfully obtained over 60 FDA product approvals.
He brings over 20 years of experience in healthcare, including diagnostics, pharmaceuticals and biotechnology. His past experiences include serving in various business development, general management and commercial roles for Johnson & Johnson, which included Commercial Director of Immunohematology for Ortho Clinical Diagnostics.
Previously he worked at Purdue Pharma running various Market Research and Commercial groups, and served as a Strategy Consultant to the healthcare industry with Monitor and McKinsey & Co consultancies.
Mr Stackawitz holds a BA in Chemistry from Dartmouth College and an MBA in Healthcare Management from The Wharton School, University of Pennsylvania.
Quotient Suisse SA
B1, Business Park Terre Bonne
Route de Crassier 13
5 James Hamilton Way
Penicuik EH26 0BF
301 S State St
Newtown, PA 18940-1997